BCDA — BioCardia, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 925741 ·
Last close
$0.82
Market Cap
$12.21M
52W High
$1.80
52W Low
$0.75
ADV30
770,333
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,266,000 | -2,259,000 | 1,712,000 | 951,000 | 2,778,000 |
| Dec 2025 | 0 | — | -2,013,000 | -1,984,000 | 3,413,000 | 2,496,000 | 2,518,000 |
| Sep 2025 | 0 | — | -1,488,000 | -1,483,000 | 6,148,000 | 5,287,000 | 3,521,000 |
| Jun 2025 | 0 | — | -2,051,000 | -2,049,000 | 2,089,000 | 980,000 | 3,975,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,477,000
Investing CF
$-10,000
Financing CF
$7,489,000
CapEx
$-12,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-170,608,000
Inventory
—
Receivables
$20,000
ST Investments
—
EBIT TTM
$-7,818,000
Pretax Income TTM
$-7,775,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,278,000 | -8,228,000 | 3,413,000 | 2,518,000 | — | -7,436,000 |
| Dec 2024 | 58,000 | -8,001,000 | -7,946,000 | 3,724,000 | 2,887,000 | — | -7,886,000 |
| Dec 2023 | 477,000 | -11,644,000 | -11,571,000 | 2,987,000 | 4,590,000 | — | -9,974,000 |
| Dec 2022 | 1,352,000 | -11,901,000 | -11,907,000 | 9,793,000 | 4,901,000 | — | -10,561,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INTS | INTENSITY THERAPEUTICS, INC. | $11.22M | $4.15 | — |
| CKDXF | Opthea Ltd | $13.68M | $0.01 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $10.62M | $0.34 | — |
| PASG | Passage BIO, Inc. | $14.36M | $4.47 | — |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $9.93M | $0.90 | — |
News headlines (Yahoo Finance, 1h cache)
Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
2026-07-28 14:32 · Yahoo
New Strong Sell Stocks for July 14th
2026-07-14 11:16 · Yahoo
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
2026-06-18 12:00 · Yahoo
BioCardia Announces $4.4 Million Financing
2026-06-08 12:00 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-05 19:49 · Yahoo
Sector Update: Healthcare Stocks Gain Friday Afternoon
2026-06-05 17:50 · Yahoo
Top Midday Gainers
2026-06-05 17:29 · Yahoo
Why Did BCDA Stock Surge More Than 50% Today?
2026-06-05 16:25 · Yahoo
BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)
2026-06-05 14:31 · Yahoo
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
2026-06-05 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.